Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Children's Qingfei Oral Liquid for Prevention and Treatment of Virus-Induced Asthma Exacerbations
ChiCTR2200060563Phase 4Not yet recruiting
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- May 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Children's Qingfei Oral Liquid in asthma and upper respiratory infection (URI) (2 arms), sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoints: Rate of acute asthma attack, Duration of acute asthma attack and 3 more. Planned start May 2022; status: not yet recruiting.
02
Drugs
Children's Qingfei Oral Liquid
03
Conditions
asthmaupper respiratory infection (URI)
Beyond the preview
Go deeper on ChiCTR2200060563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060563.